These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82). Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867 [TBL] [Abstract][Full Text] [Related]
5. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Chen Y; Hu H; Yuan X; Fan X; Zhang C Front Immunol; 2022; 13():896752. PubMed ID: 35757756 [TBL] [Abstract][Full Text] [Related]
6. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Feng MY; Chan LL; Chan SL Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172 [TBL] [Abstract][Full Text] [Related]
7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for advanced hepatocellular carcinoma, where are we? Zhang L; Ding J; Li HY; Wang ZH; Wu J Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432 [TBL] [Abstract][Full Text] [Related]
9. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Weinmann A; Galle PR Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209 [TBL] [Abstract][Full Text] [Related]
10. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Cersosimo RJ Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797 [TBL] [Abstract][Full Text] [Related]
12. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985 [TBL] [Abstract][Full Text] [Related]
13. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. Lee MMP; Chan LL; Chan SL J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044 [TBL] [Abstract][Full Text] [Related]
14. HCC and Molecular Targeting Therapies: Back to the Future. Rinaldi L; Vetrano E; Rinaldi B; Galiero R; Caturano A; Salvatore T; Sasso FC Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680462 [TBL] [Abstract][Full Text] [Related]
15. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392 [TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapies for hepatocellular carcinoma. Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464 [TBL] [Abstract][Full Text] [Related]
20. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]